References
- Baguley B.C., Calveley S.B., Crowe K.K., Fray L.M., O'Rourke S.A., Smith G.P. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours. European Journal of Cancer and Clinical Oncology 1989; 25: 263–269
- Bibby M.C., Double J.A., Phillips R.M., Loadman P.M. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). British Journal of Cancer 1987; 55: 159–163
- Bibby M.C., Double J.A., Loadman P.M. Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC347512). British Journal of Cancer 1988; 58: 341–344
- Bibby M.C., Phillips R.M., Double J.A. Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC347512). Cancer Chemotherapy and Pharmacology 1989a; 24: 87–94
- Bibby M.C., Double J.A., Loadman P.M., Duke C.V. Reduction of tumour blood flow by flavone acetic acid: A possible component of therapy. Journal of the National Cancer Institute 1989b; 81: 216–220
- Braunschweiger C.S., Johnson C.S., Kumar N., Ord V., Furmanski F. Anti-tumour effects of recombinant human Interleukin 1α in RIF-1 and Panc 02 solid tumours. Cancer Research 1988; 48: 6011–6016
- Ching L.M., Baguley B.C. Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC347512). European Journal of Cancer and Clinical Oncology 1987; 23: 1047–1050
- Corbett T.H., Bissery M.C., Wozniak A., Plowman J., Polin L., Tapazoglon E., Dieckman J., Valeriote F. Activity of flavone acetic acid (NSC-347512) against solid tumours of mice. Investigational New Drugs 1986; 4: 207–220
- Evelhoch J.L., Bissery M.C., Chabot C.G., Simpson N.E., McCoy C.L., Heilbrun L.K., Corbett T.H. Flavone acetic acid (NSC347512) induced modulation of tumour physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Research 1988; 48: 4749–4755
- Finlay G.J., Smith G.P., Fray L.M., Baguley B.C. Effect of flavone acetic acid in Lewis lung carcinoma: evidence for an indirect effect. Journal of the National Cancer Institute 1988; 80: 241–245
- Giavazzi R., Garofalo A., Damia G., Garattini J., D'Incalci M. Response to flavone acetic acid (NSC347512) of primary and metastatic colorectal carcinoma xenografts. British Journal of Cancer 1988; 57: 277–280
- Hornung R.L., Young H.A., Urba W.J., Wiltrout R.H. Immunomodulation of natural killer cell activity by flavone acetic acid: Occurrence via induction of interferon α/β. Journal of the National Cancer Institute 1988; 80: 1226–1231
- Kerr D.J., Maughan T., Newlands E., Rustin G., Bleehen N.M., Lewis C., Kaye S.B. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal cancer. British Journal of Cancer 1989; 60: 104–106
- Parr I., Wheeler E., Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. British Journal of Cancer 1973; 27: 370–389
- Plowman J., Narayanan V.L., Dykes D., Szarrasi E., Briet P., Yoder O.C., Paull K.D. Flavone acetic acid: novel agent with preclinical anti-tumour activity against colon adenocarcinoma 38 in mice. Cancer Treatment Reports 1986; 70: 631–635
- Steel G.G. Growth Kinetics of Tumours. Clarendon Press, Oxford 1977
- Wiltrout R.H., Hornung R.L. Natural products as antitumour agents: Direct versus indirect mechanisms of activity of flavonoids. Journal of the National Cancer Institute 1988; 80: 220–222
- Zwi L.J., Baguley B.C., Gavin J.B., Wilson W.R. Blood flow failure as a major determinant in the anti-tumour action of flavone acetic acid. Journal of the National Cancer Institute 1989; 81: 1005–1013